Published in Cancer Weekly, January 7th, 2003
Nipent is currently marketed by SuperGen for the treatment of hairy cell leukemia (HCL), a potentially fatal cancer of the blood and bone marrow that is characterized by a reduction in white blood cells, red blood cells, and platelets.
Highlights of Nipent-related clinical data presented at the ASH annual meeting:
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.